Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2023: USD 14.25 M

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Receivables is USD 14.25 M for the year ending December 31, 2023, a 10.47% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2022 was USD 12.89 M, a 31.37% change year over year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2021 was USD 9.82 M, a 2,345.27% change year over year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2020 was USD 401.42 K, a 139,771,589.28% change year over year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2019 was USD 0.29, a 0.00% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

CEO	Mr. Zelin Sheng
IPO Date	Jan. 23, 2020
Location	China
Headquarters	No. 209, Chenfeng Road
Employees	867
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Key trends

Past 5 years